DEPARTMENT OF HEALTH AND HUMAN SERVICES
FOOD AND DRUG ADMINISTRATION

DISTRICT ADDRESS AND PHONE NUMBER	DATE(S) OF INSPECTION
1201 Main Street, Suite 7200 Dallas, TX 75202 (214)253-5200 Fax:(214)253-5314	5/14/2026-5/14/2026
	FEI NUMBER 1628936

NAME AND TITLE OF INDIVIDUAL TO WHOM REPORT ISSUED
Barry R. Ewy, Chief Executive Officer

FIRM NAME	STREET ADDRESS
Blessings International	1650 N Indianwood Ave
CITY, STATE, ZIP CODE, COUNTRY Broken Arrow, OK 74012-1284	TYPE ESTABLISHMENT INSPECTED Drug Repackager

This document lists observations made by the FDA representative(s) during the inspection of your facility. They are inspectional observations, and do not represent a final Agency determination regarding your compliance. If you have an objection regarding an observation, or have implemented, or plan to implement, corrective action in response to an observation, you may discuss the objection or action with the FDA representative(s) during the inspection or submit this information to FDA at the address above. If you have any questions, please contact FDA at the phone number and address above.

DURING AN INSPECTION OF YOUR FIRM I OBSERVED:

OBSERVATION 1

Drug products are not stored under appropriate conditions of temperature and humidity so that their identity, strength, quality, and purity are not affected.

Specifically,

A. Temperature mapping studies have not been conducted in the warehouse, to identify worst-case locations and establish locations to monitor the warehouse conditions. Current locations for temperature/RH monitoring dataloggers are observed to be placed approximately (b) (4) from the ground, just at the (b) (4) level of the pallet storage racks, and not near drug product. Materials were observed to be stored to the (b) (4) level of the storage racks. Additionally, there is only one datalogger to record the temperature and humidity for the warehouse, which is approximately (b) (4) square feet. The firm stores and distributes tablets, capsules, ointments, and sterile injectables at this warehouse. Finished drug products include (b) (4) capsules, (b) (4) tablets, and (b) (4) sterile injection.

B. The temperature or relative humidity (RH) control limits established in the warehouse used to store finished drug products, temperature (b) (4) °F - (b) (4) °F and humidity (b) (4) % year-round, are outside the storage conditions for controlled room temperature (b) (4) °F - (b) (4) °F ((b) (4) °C - (b) (4) °C). In 2025, there were approximately 7 instances where temperature exceeded (b) (4) °F; however, a deviation investigation was not initiated, and no corrective action was taken.

OBSERVATION 2

SEE REVERSE OF THIS PAGE

EMPLOYEE(S) SIGNATURE
Melissa M Steiger, Investigator

X Melissa M Steiger Investigator Signed By: MELISSA M. STEIGER -S Date Signed: 05-14-2026 18:15:03

DATE ISSUED
5/14/2026

DEPARTMENT OF HEALTH AND HUMAN SERVICES
FOOD AND DRUG ADMINISTRATION

DISTRICT ADDRESS AND PHONE NUMBER	DATE(S) OF INSPECTION
1201 Main Street, Suite 7200 Dallas, TX 75202 (214)253-5200 Fax:(214)253-5314	5/14/2026-5/14/2026
	FEI NUMBER 1628936

NAME AND TITLE OF INDIVIDUAL TO WHOM REPORT ISSUED
Barry R. Ewy, Chief Executive Officer

FIRM NAME	STREET ADDRESS
Blessings International	1650 N Indianwood Ave
CITY, STATE, ZIP CODE, COUNTRY Broken Arrow, OK 74012-1284	TYPE ESTABLISHMENT INSPECTED Drug Repackager

Routine calibration of automatic and electronic equipment is not performed according to a written program designed to assure proper performance.

Specifically,

Calibration of the (b) (4) temperature and humidity data logger has not been performed and is used to monitor the temperature and humidity of the warehouse where finished drug products such as (b) (4) capsules, (b) (4) tablets, and (b) (4) sterile injection are stored.

SEE REVERSE OF THIS PAGE

EMPLOYEE(S) SIGNATURE
Melissa M Steiger, Investigator

X Melissa M Steiger
Investigator
Signed By: MELISSA M. STEIGER -S
Date Signed: 05-14-2026 18:15:03

DATE ISSUED
5/14/2026

The observations of objectionable conditions and practices listed on the front of this form are reported:

1. Pursuant to Section 704(b) of the Federal Food, Drug and Cosmetic Act, or
2. To assist firms inspected in complying with the Acts and regulations enforced by the Food and Drug Administration.

Section 704(b) of the Federal Food, Drug, and Cosmetic Act (21 USC 374(b)) provides:

"Upon completion of any such inspection of a factory, warehouse, consulting laboratory, or other establishment, and prior to leaving the premises, the officer or employee making the inspection shall give to the owner, operator, or agent in charge a report in writing setting forth any conditions or practices observed by him which, in his judgment, indicate that any food, drug, device, or cosmetic in such establishment (1) consists in whole or in part of any filthy, putrid, or decomposed substance, or (2) has been prepared, packed, or held under insanitary conditions whereby it may have become contaminated with filth, or whereby it may have been rendered injurious to health. A copy of such report shall be sent promptly to the Secretary."